267 related articles for article (PubMed ID: 30094870)
1. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
O'Brien S; Patel M; Kahl BS; Horwitz SM; Foss FM; Porcu P; Jones J; Burger J; Jain N; Allen K; Faia K; Douglas M; Stern HM; Sweeney J; Kelly P; Kelly V; Flinn I
Am J Hematol; 2018 Nov; 93(11):1318-1326. PubMed ID: 30094870
[TBL] [Abstract][Full Text] [Related]
2. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Flinn IW; Hillmen P; Montillo M; Nagy Z; Illés Á; Etienne G; Delgado J; Kuss BJ; Tam CS; Gasztonyi Z; Offner F; Lunin S; Bosch F; Davids MS; Lamanna N; Jaeger U; Ghia P; Cymbalista F; Portell CA; Skarbnik AP; Cashen AF; Weaver DT; Kelly VM; Turnbull B; Stilgenbauer S
Blood; 2018 Dec; 132(23):2446-2455. PubMed ID: 30287523
[TBL] [Abstract][Full Text] [Related]
3. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
Flinn IW; O'Brien S; Kahl B; Patel M; Oki Y; Foss FF; Porcu P; Jones J; Burger JA; Jain N; Kelly VM; Allen K; Douglas M; Sweeney J; Kelly P; Horwitz S
Blood; 2018 Feb; 131(8):877-887. PubMed ID: 29191916
[TBL] [Abstract][Full Text] [Related]
4. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.
Davids MS; Kuss BJ; Hillmen P; Montillo M; Moreno C; Essell J; Lamanna N; Nagy Z; Tam CS; Stilgenbauer S; Ghia P; Delgado J; Lustgarten S; Weaver DT; Youssoufian H; Jäger U
Clin Cancer Res; 2020 May; 26(9):2096-2103. PubMed ID: 31964785
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
7. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
[TBL] [Abstract][Full Text] [Related]
8. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Makita S; Ota S; Mishima Y; Usuki K; Ennishi D; Yanada M; Fukuhara N; Yamamoto R; Takamine A; Nohara G; Izutsu K
Int J Hematol; 2024 Feb; 119(2):156-163. PubMed ID: 38150138
[TBL] [Abstract][Full Text] [Related]
9. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
[TBL] [Abstract][Full Text] [Related]
10. Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
Flinn IW; Patel M; Oki Y; Horwitz S; Foss FF; Allen K; Douglas M; Stern H; Sweeney J; Kharidia J; Kelly P; Kelly VM; Kahl B
Am J Hematol; 2018 Nov; 93(11):1311-1317. PubMed ID: 30033575
[TBL] [Abstract][Full Text] [Related]
11. Duvelisib for the treatment of chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Expert Opin Pharmacother; 2020 Aug; 21(11):1299-1309. PubMed ID: 32292084
[TBL] [Abstract][Full Text] [Related]
12. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.
Izutsu K; Kato K; Kiyoi H; Yamamoto G; Shimada K; Akashi K
Int J Hematol; 2020 Oct; 112(4):504-509. PubMed ID: 32613313
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Davids MS; Fisher DC; Tyekucheva S; McDonough M; Hanna J; Lee B; Francoeur K; Montegaard J; Odejide O; Armand P; Arnason J; Brown JR
Leukemia; 2021 Apr; 35(4):1064-1072. PubMed ID: 32820271
[TBL] [Abstract][Full Text] [Related]
15. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.
Vangapandu HV; Jain N; Gandhi V
Expert Opin Investig Drugs; 2017 May; 26(5):625-632. PubMed ID: 28388280
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs.
Shao Y; Xie S; Zhu H; Du X; Xu RA
J Pharm Biomed Anal; 2020 Aug; 187():113355. PubMed ID: 32442869
[TBL] [Abstract][Full Text] [Related]
17. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Hanlon A; Brander DM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
[TBL] [Abstract][Full Text] [Related]
18. Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.
Shah A; Barrientos JC
Onco Targets Ther; 2021; 14():2109-2119. PubMed ID: 33790574
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
20. Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies.
Xu W; Yang S; Tam CS; Seymour JF; Zhou K; Opat S; Qiu L; Sun M; Wang T; Trotman J; Pan L; Gao S; Zhou J; Zhou D; Zhu J; Song Y; Hu J; Feng R; Huang H; Su D; Shi M; Li J
Adv Ther; 2022 Sep; 39(9):4250-4265. PubMed ID: 35900694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
